This is a Phase II, randomized, parallel-group, double-blind, placebo-controlled study of sonelokimab in participants with active moderate to severe HS. This study aims to evaluate the safety and efficacy of 2 different doses of sonelokimab in treating HS, in comparison to the placebo. The study includes a screening period of up to 28 days, a 24-week treatment period and a 4-week safety follow-up period. For the first 12 weeks, adalimumab will be used as a reference treatment.
This study aims to evaluate the safety and efficacy of isotretinoin ointment (TMB-001 0.05%) in treating subjects > or = to 6 years of age with lamellar ichthyosis, and aims to assess the bodily absorption of the cream across application frequencies. Subjects with ARCI/RXLI will be randomized 2:1, to either receive the TMB-001 0.05% isotretinoin ointment or a vehicle ointment - applied daily - for 3 weeks. Subsequently, dosing will be increased to twice daily for 9 weeks. If significant improvement is observed at the end of the 9 weeks, subjects will be randomized 1:1 to receive the TMB-001 0.05% ointment, either applied daily or twice-daily, for 12 weeks. Prior to the Phase III trial, subjects will have the option to participate in a 14 day treatment period with TMB-001 0.05% - twice daily - followed by continued treatment with TMB-001 0.05% twice daily for 10 weeks.
This study is designed to assess the efficacy, safety and tolerability of selected systemic investigational treatments for 16 weeks in moderate to severe hidradenitis suppurativa (HS) subjects. Data from this study will enable determination of whether the clinical profile of these investigational treatments support further clinical development in moderate to severe HS.
The purpose of this open-label extension study is to help us understand how safe and effective a new investigational drug called bimekizumab is for long-term use in treating hidradenitis suppurativa. This study will involve approximately 830 study participants across approximately 200 centers. Participants will either receive 320mg bimekizumab once every two weeks or 320mg bimekizumab once every four weeks. The total duration of the study will be up to 118 weeks. This study includes a total of 52 study visits.
The purpose of this study is to find out how long ustekinumab stays in and acts in participant's who are diagnosed with pediatric psoriasis and juvenile psoriatic arthritis. This is measured by blood tests. Another purpose is to find out if ustekinumab can cause side effects, which are unexpected or unwanted reactions from taking a drug. About 75 children will take part in this study worldwide. Participants will be in the study for a maximum of about 16 weeks.
The purpose of this research study is to develop a better understanding of the cause and natural history of vascular anomalies and related syndromes. This study is being done in order to develop a better understanding of the cause of vascular anomalies in order to to improve care for people who are affected by these anomalies and related syndromes.
This study is being done at the University of Wisconsin-Madison (UW-Madison) and other sites in North America and Europe. A total of about 1000 people will participate in this study. About 20 – 30 people will take part in the study here at the Medical University of South Carolina.
The purpose of this research study is to determine if an investigational cream, ruxolitinib cream (0.75% and 1.5% strengths), is safe and effective to treat Atopic Dermatitis. In this study, ruxolitinib cream will be compared to a "vehicle cream." The vehicle cream looks like the ruxolitinib cream but contains no ruxolitinib. This study can last up to 55 weeks. For the first 8 weeks participants will be randomly assigned to receive either the ruxolitinib cream or vehicle cream. For the following 44 weeks participants will receive the ruxolitinib cream.
The purpose of this study is to test and compare the effects of an investigational drug called Upadacitinib versus placebo in adults aged 18 to 65 with a diagnosis of non-segmented vitiligo. Participants that meet eligibility criteria will be randomized into 1 of 5 treatments groups for a period of 24 weeks. At week 24, participants who were randomized to placebo will be switched to either 22 or 11 mg upadacitinib in a blinded fashion, while those receiving the drug will remain in their randomized treatment at week 24. This will be a 28 week blinded long-term extension.
The purpose of this study is to test and compare the effects of investigational drug risankizumab to the active control, ustekinumab, on pediatric plaque psoriasis. Subjects that meet all eligibility criteria will be randomized 2:1 to receive 150 mg dose of risankizumab and 45mg or 90 mg dose of ustekinumab - both drug dosages are determined by weight. At Week 16, subjects receiving ustekinumab or are unresponsive to risankizumab, will be switched to or continue to receive 150 mg risankizumab every 12 weeks. Subjects that are responsive to risankizumab at Week 16, will be re-randomized 1:1 to continue risankizumab or withdrawal from the study drug. Subjects randomized to withdrawal will receive no study drug until a flare occurs, after which they will enter a 16-week re-treatment period.
This study is being done to evaluate the safety and efficacy of ARQ-151 cream in subjects with mild to moderate eczema (atopic dermatitis) after application once every day for a month. Results will be compared against a vehicle (placebo). The vehicle is a dummy drug made from the same base product used to make ARQ-151 cream, but it does not contain any active study drug. ARQ-151 is a cream that contains the active ingredient roflumilast. Roflumilast is marketed in Canada, the United States, and other countries as a tablet (pill taken by mouth) for flares of a specific chronic lung disease. You will apply the study drug on your eczema lesions once a day for 28 days. The study doctor will tell you which lesions to treat. Any newly appearing eczema lesions that arise during the study must also be treated.